TW200819123A - Methods of treatment using alpha-2-delta-1 selective compounds - Google Patents

Methods of treatment using alpha-2-delta-1 selective compounds Download PDF

Info

Publication number
TW200819123A
TW200819123A TW096123873A TW96123873A TW200819123A TW 200819123 A TW200819123 A TW 200819123A TW 096123873 A TW096123873 A TW 096123873A TW 96123873 A TW96123873 A TW 96123873A TW 200819123 A TW200819123 A TW 200819123A
Authority
TW
Taiwan
Prior art keywords
compound
pain
condition
ligand
selective
Prior art date
Application number
TW096123873A
Other languages
English (en)
Chinese (zh)
Inventor
Zheng Li
Jacob Bradley Schwarz
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TW200819123A publication Critical patent/TW200819123A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW096123873A 2006-06-30 2007-06-29 Methods of treatment using alpha-2-delta-1 selective compounds TW200819123A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81815406P 2006-06-30 2006-06-30

Publications (1)

Publication Number Publication Date
TW200819123A true TW200819123A (en) 2008-05-01

Family

ID=38739992

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096123873A TW200819123A (en) 2006-06-30 2007-06-29 Methods of treatment using alpha-2-delta-1 selective compounds

Country Status (4)

Country Link
JP (1) JP2008013555A (es)
AR (1) AR061728A1 (es)
TW (1) TW200819123A (es)
WO (1) WO2008004067A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0817173A2 (pt) 2007-11-05 2015-12-01 Unilever Nv processo e folha de chá capaz de ser obtida pelo processo
CN110945014A (zh) * 2017-05-26 2020-03-31 诺瓦色生物公司 电压门控钙通道缺陷亚基α2δ及其应用
WO2021079887A1 (ja) * 2019-10-25 2021-04-29 国立大学法人京都大学 タウオパチーの予防又は治療剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20094817B (en) * 1997-10-27 2009-11-10 Warner Lambert Co Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
NZ503963A (en) * 1997-12-16 2002-09-27 Warner Lambert Co 1-substituted-1-aminomethyl-cycloalkane derivatives, or gabapentin analogues, preparation and use in the treatment of neurological disorders
CZ301608B6 (cs) * 1999-06-10 2010-04-28 Warner-Lambert Company Derivát 3-propyl gamma-aminomáselné kyseliny a farmaceutický prostredek s jeho obsahem
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
CA2444053C (en) * 2001-04-19 2008-06-17 Warner-Lambert Company Llc Fused bicyclic or tricyclic amino acids
NI200300043A (es) * 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
GB0225379D0 (en) * 2002-10-31 2002-12-11 Pfizer Ltd Therapeutic proline derivatives
KR100768974B1 (ko) * 2003-09-25 2007-10-22 워너-램버트 캄파니 엘엘씨 알파2델타-단백질에 대한 친화성을 갖는 아미노산
WO2005102390A2 (en) * 2004-04-22 2005-11-03 Pfizer Japan, Inc. Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
WO2006017293A2 (en) * 2004-07-13 2006-02-16 Regents Of The University Of California Models and methods for nociception, pain transduction, and screening for analgesic compounds
WO2006100606A2 (en) * 2005-03-24 2006-09-28 Warner-Lambert Company Llc Preparation of beta-amino acid precursors via indium (iii) mediated markovnikov addition and knoevenagel condensation

Also Published As

Publication number Publication date
WO2008004067A2 (en) 2008-01-10
AR061728A1 (es) 2008-09-17
WO2008004067A3 (en) 2009-01-29
JP2008013555A (ja) 2008-01-24

Similar Documents

Publication Publication Date Title
AU2016200765B2 (en) Methods for treating fibromyalgia syndrome
CA2801243C (en) Methods of treating restless legs syndrome
ES2447295T3 (es) Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad
CA2801241C (en) Methods for treating bipolar disorder
JPH06509561A (ja) 新規中枢神経作用性置換フェニルアザシクロアルカン類
RU2331438C2 (ru) Альфа-2-дельта лиганд для лечения симптомов нижних мочевыводящих путей
RU2320369C2 (ru) Комбинации, содержащие альфа-2-дельта лиганды и ингибиторы обратного захвата серотонина/норадреналина
TW201116273A (en) Co-crystals of tramadol and coxibs
TW200819123A (en) Methods of treatment using alpha-2-delta-1 selective compounds
ES2421171T3 (es) Inhibidores de reabsorción triples y su uso en métodos
JP2007506726A (ja) α２δ−タンパク質に対する親和性を有するアミノ酸の使用方法
US20220259164A1 (en) Use of aminothiol compounds as cerebral nerve or heart protective agent
SA515360518B1 (ar) مشتقات أمينو سيكلو بيوتان، وطريقة لتحضيرها، واستخدامها كعقاقير
JP7295145B2 (ja) 神経変性疾患を治療するための医薬及びその使用
RU2700595C1 (ru) Производное 3,6,9-триазатрициклотетрадекана и его применение для лечения депрессии
RU2776845C2 (ru) Аналоги целастрола
JP2024522632A (ja) 自閉症スペクトラム障害（ａｓｄ）を治療する方法
JP2005506986A (ja) 選択的ｉｎｏｓ阻害剤を用いる眼科治療方法